Details of the Drug

General Information of Drug (ID: DMN6DXL)

• Drug Name: Risperidone
• Synonyms: Belivon; Risperdal; Risperdone; Risperidal; Risperidona; Risperidonum; Risperin; Rispolept; Rispolin; Sequinan; Risperdal Consta; Risperidona [Spanish]; Risperidonum [Latin]; R 62 766; R 64766; R64766; Consta, Risperdal; KS-1106; R 64,766; R-118; R-64766; R64,766; Risperdal (TN); Risperdal M-Tab; Risperidal M-Tab; Risperidone (RIS); Risperidone, placebo; R 64 766, Risperdal, Risperidone; R-64,766; R-64-766; Risperidone [USAN:BAN:INN]; Risperidone (JAN/USAN/INN); 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Indication

Disease Entry	ICD 11	Status	REF
Bipolar I disorder	N.A.	Approved	[1]
Schizoaffective disorder	6A21	Approved	[1]
Schizophrenia	6A20	Approved	[2]
Autism	N.A.	Investigative	[1]

• Therapeutic Class: Antipsychotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 410.5
  Logarithm of the Partition Coefficient (xlogp); 2.7
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 200 mcg/L [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: 66% of drug becomes completely available to its intended biological destination(s) [5]
  Clearance: The clearance of drug is 15-59 mL/min [6]
  Elimination: 3% of drug is excreted from urine in the unchanged form [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3 hours [7]
  Metabolism: The drug is metabolized via the hepatic cytochrome P450 2D6 isozyme to 9-hydroxyrisperidone [8]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.555 micromolar/kg/day [9]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.1% [10]
  Vd: The volume of distribution (Vd) of drug is 1-2 L/kg [11]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.25 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Tardive dyskinesia	Not Available	DRD4	OTAJTO7N	[12]

• Chemical Identifiers:
  Formula: C23H27FN4O2
  IUPAC Name: 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
  Canonical SMILES: CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
  InChI: InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
  InChIKey: RAPZEAPATHNIPO-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5073
  ChEBI ID: CHEBI:8871
  DrugBank ID: DB00734
  TTD ID: D01AZG
  VARIDT ID: DR00384
  INTEDE ID: DR1428
  ACDINA ID: D00599
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[13]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[15]
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[16]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[17]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[18]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Drug Response	[19]
5-hydroxytryptamine receptor 2C (HTR2C)	OT6H8DE0	5HT2C_HUMAN	Drug Response	[20]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Drug Response	[21]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[20]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[22]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[22]
Corticoliberin (CRH)	OT2MOC4T	CRF_HUMAN	Gene/Protein Processing	[23]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Biotransformations	[24]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Drug Response	[25]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 06 Mental, behavioural or neurodevelopmental disorder
• Disease Class: ICD-11: 6A20 Schizophrenia
• The Studied Tissue: Pre-frontal cortex
• The Studied Disease: Schizophrenia [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	9.39E-01	-0.01	-0.05
Dopamine D2 receptor (D2R)	DTT	DRD2	9.91E-01	-0.02	-0.28
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.19E-01	-1.32E-01	-2.77E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.65E-01	-1.47E-01	-4.48E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	1.17E-01	-3.87E-02	-2.23E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.74E-01	7.48E-03	1.37E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.59E-01	6.29E-02	3.14E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	4.84E-01	-8.38E-02	-8.46E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.66E-01	4.25E-02	1.20E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.75E-01	5.15E-02	3.64E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Risperidone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Risperidone and Mesoridazine.	Schizophrenia [6A20]	[26]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Risperidone and Aripiprazole.	Schizophrenia [6A20]	[27]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Risperidone and Iloperidone.	Schizophrenia [6A20]	[26]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Paliperidone.	Schizophrenia [6A20]	[26]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Risperidone and Molindone.	Schizophrenia [6A20]	[27]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Risperidone and Thiothixene.	Schizophrenia [6A20]	[27]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Risperidone and Trifluoperazine.	Schizophrenia [6A20]	[27]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Risperidone and Amisulpride.	Schizophrenia [6A20]	[28]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Asenapine.	Schizophrenia [6A20]	[26]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Risperidone and Pimozide.	Schizophrenia [6A20]	[29]

Coadministration of a Drug Treating the Disease Different from Risperidone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Risperidone and Ivosidenib.	Acute myeloid leukaemia [2A60]	[30]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Midostaurin.	Acute myeloid leukaemia [2A60]	[26]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Idarubicin.	Acute myeloid leukaemia [2A60]	[26]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Risperidone and Oliceridine.	Acute pain [MG31]	[31]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Risperidone and Scopolamine.	Addictive disorder [6C50-6C5Z]	[27]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Risperidone and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[32]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Risperidone and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[32]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Risperidone and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[27]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Risperidone and Memantine.	Alzheimer disease [8A20]	[27]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Risperidone when combined with Rivastigmine.	Alzheimer disease [8A20]	[33]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Risperidone when combined with Donepezil.	Alzheimer disease [8A20]	[33]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Risperidone and Metronidazole.	Amoebiasis [1A36]	[34]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Risperidone and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[35]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Risperidone and Ivabradine.	Angina pectoris [BA40]	[29]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Risperidone and Bepridil.	Angina pectoris [BA40]	[26]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Risperidone and Amyl nitrite.	Angina pectoris [BA40]	[35]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Risperidone and Nifedipine.	Angina pectoris [BA40]	[35]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Risperidone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[36]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Cilostazol.	Arterial occlusive disease [BD40]	[26]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Posaconazole.	Aspergillosis [1F20]	[26]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Levalbuterol.	Asthma [CA23]	[37]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Terbutaline.	Asthma [CA23]	[38]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Pirbuterol.	Asthma [CA23]	[38]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Salbutamol.	Asthma [CA23]	[37]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Formoterol.	Asthma [CA23]	[38]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Risperidone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[27]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[26]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Risperidone and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[26]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Risperidone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[39]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[39]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[39]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[39]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[26]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Telithromycin.	Bacterial infection [1A00-1C4Z]	[26]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Retigabine.	Behcet disease [4A62]	[26]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Risperidone and Loperamide.	Bowel habit change [ME05]	[40]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Eribulin.	Breast cancer [2C60-2C6Y]	[26]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Lapatinib.	Breast cancer [2C60-2C6Y]	[26]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Risperidone when combined with Acetylcholine.	Cataract [9B10]	[41]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[42]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Risperidone and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[43]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[38]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Risperidone and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[43]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[38]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Risperidone and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[43]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[38]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[38]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Risperidone and Dihydrocodeine.	Chronic pain [MG30]	[44]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Isoproterenol.	Conduction disorder [BC63]	[37]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Risperidone and Olopatadine.	Conjunctiva disorder [9A60]	[45]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Halothane.	Corneal disease [9A76-9A78]	[26]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Propofol.	Corneal disease [9A76-9A78]	[46]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Sevoflurane.	Corneal disease [9A76-9A78]	[26]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Risperidone and Alfentanil.	Corneal disease [9A76-9A78]	[31]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Risperidone and Remifentanil.	Corneal disease [9A76-9A78]	[31]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Probucol.	Coronary atherosclerosis [BA80]	[26]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Clofazimine.	Crohn disease [DD70]	[47]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Risperidone and Mifepristone.	Cushing syndrome [5A70]	[26]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Osilodrostat.	Cushing syndrome [5A70]	[29]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Risperidone and Ethanol.	Cystitis [GC00]	[45]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Risperidone and Cyclandelate.	Dementia [6D80-6D8Z]	[35]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Risperidone and Escitalopram.	Depression [6A70-6A7Z]	[26]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Risperidone and OPC-34712.	Depression [6A70-6A7Z]	[27]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Risperidone and Clomipramine.	Depression [6A70-6A7Z]	[27]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Risperidone and Doxepin.	Depression [6A70-6A7Z]	[27]
Maprotiline	DMPWB7T	Moderate	Decreased metabolism of Risperidone caused by Maprotiline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Risperidone and Esketamine.	Depression [6A70-6A7Z]	[34]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Risperidone and Mepenzolate.	Digestive system disease [DE2Z]	[27]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Risperidone and Oxybutynine.	Discovery agent [N.A.]	[27]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Risperidone and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[49]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Risperidone and Meclizine.	Dizziness and giddiness [MB48]	[27]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Risperidone and Deutetrabenazine.	Dystonic disorder [8A02]	[50]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Ingrezza.	Dystonic disorder [8A02]	[51]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Risperidone and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[52]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Risperidone when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[53]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Ethacrynic acid.	Essential hypertension [BA00]	[34]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Risperidone and Phenoxybenzamine.	Essential hypertension [BA00]	[35]
Guanethidine	DM9NSWT	Moderate	Additive hypotensive effects by the combination of Risperidone and Guanethidine.	Essential hypertension [BA00]	[35]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Risperidone and Nadolol.	Essential hypertension [BA00]	[35]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Solifenacin.	Functional bladder disorder [GC50]	[26]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Risperidone caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[54]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Risperidone and Tolterodine.	Functional bladder disorder [GC50]	[27]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Pentamidine.	Fungal infection [1F29-1F2F]	[26]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Risperidone caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[55]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Ketoconazole.	Fungal infection [1F29-1F2F]	[26]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Risperidone and Propantheline.	Gastric ulcer [DA60]	[27]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[26]
Acetazolamide	DM1AF5U	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Acetazolamide.	Glaucoma [9C61]	[34]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Risperidone when combined with Pilocarpine.	Glaucoma [9C61]	[41]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Risperidone and Carvedilol.	Heart failure [BD10-BD1Z]	[35]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Chlorothiazide.	Heart failure [BD10-BD1Z]	[34]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Bumetanide.	Heart failure [BD10-BD1Z]	[34]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[34]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Risperidone due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Risperidone and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Risperidone and Isosorbide mononitrate.	Hydrocephalus [8D64]	[35]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Risperidone caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[34]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Risperidone and Eprosartan.	Hypertension [BA00-BA04]	[35]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Risperidone and Acebutolol.	Hypertension [BA00-BA04]	[35]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Risperidone and Captopril.	Hypertension [BA00-BA04]	[35]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Risperidone and Penbutolol.	Hypertension [BA00-BA04]	[35]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Risperidone and Methyldopa.	Hypertension [BA00-BA04]	[35]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Risperidone and Nebivolol.	Hypertension [BA00-BA04]	[35]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Risperidone and Levamlodipine.	Hypertension [BA00-BA04]	[35]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Risperidone and TAK-491.	Hypertension [BA00-BA04]	[35]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Risperidone and Pindolol.	Hypertension [BA00-BA04]	[35]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Risperidone and Fenoldopam.	Hypertension [BA00-BA04]	[35]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Indapamide.	Hypertension [BA00-BA04]	[34]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Trichlormethiazide.	Hypertension [BA00-BA04]	[34]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Risperidone and Diazoxide.	Hypertension [BA00-BA04]	[35]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Risperidone and Perindopril.	Hypertension [BA00-BA04]	[35]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Risperidone and Felodipine.	Hypertension [BA00-BA04]	[35]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Risperidone and Quinapril.	Hypertension [BA00-BA04]	[35]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Risperidone and Deserpidine.	Hypertension [BA00-BA04]	[35]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Risperidone and Telmisartan.	Hypertension [BA00-BA04]	[35]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Risperidone and Irbesartan.	Hypertension [BA00-BA04]	[35]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Risperidone and Hydralazine.	Hypertension [BA00-BA04]	[35]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[34]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Risperidone and Clevidipine butyrate.	Hypertension [BA00-BA04]	[35]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Risperidone caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[59]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Risperidone and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[27]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Risperidone and Amantadine.	Influenza [1E30-1E32]	[60]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Risperidone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[61]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Risperidone and Propiomazine.	Insomnia [7A00-7A0Z]	[27]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Risperidone and ITI-007.	Insomnia [7A00-7A0Z]	[27]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Risperidone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[26]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Phenolphthalein.	Irritable bowel syndrome [DD91]	[26]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Risperidone and Clidinium.	Irritable bowel syndrome [DD91]	[27]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Risperidone and Dicyclomine.	Irritable bowel syndrome [DD91]	[27]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Risperidone when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[33]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Risperidone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[29]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Risperidone and Crizotinib.	Lung cancer [2C25]	[62]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Risperidone and Ceritinib.	Lung cancer [2C25]	[26]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Risperidone caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[63]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Risperidone and Osimertinib.	Lung cancer [2C25]	[64]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Risperidone and Selpercatinib.	Lung cancer [2C25]	[29]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Risperidone and Lumefantrine.	Malaria [1F40-1F45]	[34]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Risperidone and Halofantrine.	Malaria [1F40-1F45]	[65]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Risperidone and Hydroxychloroquine.	Malaria [1F40-1F45]	[66]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Primaquine.	Malaria [1F40-1F45]	[26]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[29]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Risperidone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[67]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Risperidone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[68]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Risperidone and Vemurafenib.	Melanoma [2C30]	[26]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and LGX818.	Melanoma [2C30]	[69]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Risperidone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[70]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Risperidone and Lasmiditan.	Migraine [8A80]	[71]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Risperidone and Flibanserin.	Mood disorder [6A60-6E23]	[72]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Risperidone and Panobinostat.	Multiple myeloma [2A83]	[73]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Risperidone and Thalidomide.	Multiple myeloma [2A83]	[74]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Risperidone and Siponimod.	Multiple sclerosis [8A40]	[34]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Risperidone and Fingolimod.	Multiple sclerosis [8A40]	[26]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Risperidone and Ozanimod.	Multiple sclerosis [8A40]	[75]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Romidepsin.	Mycosis fungoides [2B01]	[26]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Risperidone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[29]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Dasatinib.	Myeloproliferative neoplasm [2A20]	[76]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Risperidone and Phenindamine.	Nasopharyngitis [CA00]	[27]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Risperidone and Dimenhydrinate.	Nausea/vomiting [MD90]	[27]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Risperidone and Promethazine.	Nausea/vomiting [MD90]	[27]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Risperidone caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[77]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Risperidone and Cyclizine.	Nausea/vomiting [MD90]	[27]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Risperidone and Dolasetron.	Nausea/vomiting [MD90]	[26]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Ondansetron.	Nausea/vomiting [MD90]	[26]
Bupropion	DM5PCS7	Major	Decreased metabolism of Risperidone caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[26]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Entrectinib.	Non-small cell lung cancer [2C25]	[34]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Risperidone and Lorcaserin.	Obesity [5B80-5B81]	[78]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Polythiazide.	Oedema [MG29]	[34]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Risperidone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[29]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Lofexidine.	Opioid use disorder [6C43]	[26]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Risperidone and Apraclonidine.	Optic nerve disorder [9C40]	[79]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Rucaparib.	Ovarian cancer [2C73]	[26]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Risperidone and Oxymorphone.	Pain [MG30-MG3Z]	[31]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Risperidone and Levorphanol.	Pain [MG30-MG3Z]	[31]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Risperidone and Dezocine.	Pain [MG30-MG3Z]	[31]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Risperidone and Flavoxate.	Pain [MG30-MG3Z]	[27]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Risperidone and Nalbuphine.	Pain [MG30-MG3Z]	[31]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Risperidone and Buprenorphine.	Pain [MG30-MG3Z]	[80]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Triclabendazole.	Parasitic worm infestation [1F90]	[26]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Risperidone when combined with Pergolide.	Parkinsonism [8A00]	[81]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Risperidone when combined with Opicapone.	Parkinsonism [8A00]	[81]
Biperiden	DME78OA	Moderate	Antagonize the effect of Risperidone when combined with Biperiden.	Parkinsonism [8A00]	[53]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Risperidone when combined with Levodopa.	Parkinsonism [8A00]	[81]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Pimavanserin.	Parkinsonism [8A00]	[82]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Risperidone and Orphenadrine.	Parkinsonism [8A00]	[27]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Risperidone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[83]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Famotidine.	Peptic ulcer [DA61]	[34]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Risperidone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[84]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Risperidone and Lefamulin.	Pneumonia [CA40]	[85]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[34]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Risperidone and Ritodrine.	Preterm labour/delivery [JB00]	[38]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Degarelix.	Prostate cancer [2C82]	[29]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Risperidone caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[86]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Enzalutamide.	Prostate cancer [2C82]	[29]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Relugolix.	Prostate cancer [2C82]	[29]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Bicalutamide.	Prostate cancer [2C82]	[29]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Risperidone and Terazosin.	Prostate hyperplasia [GA90]	[35]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Risperidone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[27]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Risperidone and Tolazoline.	Pulmonary hypertension [BB01]	[35]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Risperidone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[87]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Risperidone when combined with Neupro.	Restless legs syndrome [7A80]	[81]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Risperidone and Fentanyl.	Sensation disturbance [MB40]	[31]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Vardenafil.	Sexual dysfunction [HA00-HA01]	[26]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Risperidone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[34]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Risperidone and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[26]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Risperidone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[26]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[29]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[26]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Pitolisant.	Somnolence [MG42]	[26]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[26]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Risperidone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[88]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Lenvatinib.	Thyroid cancer [2D10]	[26]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Risperidone and Cabozantinib.	Thyroid cancer [2D10]	[29]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Risperidone and Papaverine.	Tonus and reflex abnormality [MB47]	[35]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Tacrolimus.	Transplant rejection [NE84]	[26]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Risperidone and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[27]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Risperidone and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[27]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Risperidone and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[27]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Risperidone and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[32]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Risperidone and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[27]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Risperidone and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[27]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Risperidone and Procainamide.	Ventricular tachyarrhythmia [BC71]	[26]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Propafenone.	Ventricular tachyarrhythmia [BC71]	[26]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Risperidone and Flecainide.	Ventricular tachyarrhythmia [BC71]	[26]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Risperidone and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[26]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Allura red AC dye	E00338	33258	Colorant
Aminoethanoic acid	E00025	750	Buffering agent; Disintegrant; Lyophilization aid
Aspartame	E00402	134601	Flavoring agent
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
D&C brown no. 1	E00565	23675104	Colorant
D&C green no. 5	E00265	20431	Colorant
Docusate sodium	E00563	23673837	Surfactant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Menthol	E00050	1254	Flavoring agent
Monoammonium glycyrrhizate	E00352	62074	Emulsifying agent; Flavoring agent
Pigment orange 2	E00379	80852	Colorant
Pigment yellow 3	E00388	94326	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium carbonate	E00205	11029	Adsorbent; Diluent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid	E00029	875	Acidulant; Complexing agent; Flavoring agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Risperidone 0.25 mg tablet	0.25 mg	Disintegrating Oral Tablet	Oral
Risperidone 2 mg tablet	2 mg	Oral Tablet	Oral
Risperidone 0.5 mg tablet	0.5 mg	Disintegrating Oral Tablet	Oral
Risperidone 1 mg tablet	1 mg	Disintegrating Oral Tablet	Oral
Risperidone 2 mg tablet	2 mg	Disintegrating Oral Tablet	Oral
Risperidone 3 mg tablet	3 mg	Disintegrating Oral Tablet	Oral
Risperidone 4 mg tablet	4 mg	Disintegrating Oral Tablet	Oral
Risperidone 0.25 mg tablet	0.25 mg	Oral Tablet	Oral
Risperidone 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Risperidone 1 mg tablet	1 mg	Oral Tablet	Oral
Risperidone 4 mg tablet	4 mg	Oral Tablet	Oral
Risperidone 3 mg tablet	3 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Risperidone FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 96).
• [3] Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep;12(5):741-56. doi: 10.1517/14740338.2013.806481. Epub 2013 Jun 6.
• [4] BDDCS applied to over 900 drugs
• [5] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [6] Pharmacokinetics of Risperidone: Clinical Summary
• [7] Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994 May;114(4):566-72.
• [8] Takahiro M, Haruo I, Toshihiko, I: Identification of Gemfibrozil Metabolites, Produced as Positional Isomers in Human Liver Microsomes, by On-line Analyses Using Liquid Chromatography/Mass Spectrometry and Liquid Chromatography/Nuclear Magnetic Resonance Spectroscopy J. Mass Spectrom. Soc. Jpn.. 2004 Jun 6;52(5):277-283.
• [9] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [10] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [11] FDA Approved Drug Products: Risperdal (risperidone) for oral use
• [12] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [13] Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
• [14] Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005 Jul;78(1):43-51.
• [15] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [16] Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005 Nov;78(5):520-8.
• [17] Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
• [18] Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 2006 Oct 20;7:69.
• [19] Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. 2006 Jan-Feb;6(1):42-51. doi: 10.1038/sj.tpj.6500342.
• [20] Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010 Oct;10(5):418-30.
• [21] Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia. J Clin Psychopharmacol. 2012 Jun;32(3):394-7. doi: 10.1097/JCP.0b013e31825370f4.
• [22] Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
• [23] Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology. 2006 Apr;31(4):853-65. doi: 10.1038/sj.npp.1300911.
• [24] Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):261-8. doi: 10.1007/s00406-004-0556-4. Epub 2004 Nov 29.
• [25] Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol. 2010 Jul;24(7):1115-20. doi: 10.1177/0269881109104932. Epub 2009 Apr 24.
• [26] Canadian Pharmacists Association.
• [27] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [28] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [29] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [30] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [31] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [32] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [33] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [34] Cerner Multum, Inc. "Australian Product Information.".
• [35] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [36] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [37] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [38] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [39] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [40] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [41] Multum Information Services, Inc. Expert Review Panel.
• [42] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [43] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [44] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [45] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [46] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [47] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [48] Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7. [PMID: 7251568]
• [49] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [50] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [51] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [52] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [53] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [54] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [55] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [56] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [57] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [58] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [59] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [60] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [61] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [62] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [63] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [64] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [65] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [66] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [67] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [68] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [69] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [70] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [71] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [72] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [73] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [74] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [75] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [76] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [77] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [78] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [79] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [80] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [81] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [82] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [83] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [84] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [85] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [86] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [87] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [88] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.